Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Bonomo, Robert A ^a   Szabo, Dora ^b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFALOTIN; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORINASE; CEPHAMYCIN; DNA TOPOISOMERASE; IMIPENEM; OUTER MEMBRANE PROTEIN; OXACILLIN; PENICILLIN G; POLYMYXIN; PORIN; TICARCILLIN; AMINOGLYCOSIDE; CARRIER PROTEIN; QUINOLONE DERIVATIVE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME MODIFICATION; GENE MUTATION; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RECEPTOR UPREGULATION; SPECIES DIFFERENTIATION; CROSS INFECTION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; REVIEW;

ACINETOBACTER; AMINOGLYCOSIDES; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; PORINS; PSEUDOMONAS AERUGINOSA; QUINOLONES;

EID: 33747625237     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504477     Document Type: Conference Paper

References (131)

1. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146:837.
2. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
4. Joly-Guillo ML, Vallee E, Bergogne-Berezin E, Philippon A. Distribution of β-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. J Antimicrob Chemother 1988; 22:597-604.
5. Blechschmidt B, Borneleit P, Kleber HP. Purification and characterization of an extracellular β-lactamase produced by Acinetobacter calcoaceticus. J Gen Microbiol 1992; 138:1197-202.
6. Vila J, Marcos A, Marco F, et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37:138-41.
7. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003; 52:629-35.
8. Mammeri H, Poirel L, Mangeney N, Nordmann P. Chromosomal integration of a cephalosporinase gene from Acinetobacter baumannii into Oligella urethralis as a source of acquired resistance to β-lactams. Antimicrob Agents Chemother 2003; 47:1536-42.
9. Lopez-Hernandez S, Alarcon T, Lopez-Brea M. Biochemical characterization of chromosomal cephalosporinases from isolates belonging to the Acinetobacter baumannii complex. Clin Microbiol Infect 2001; 7: 218-26.
10. Beceiro A, Dominguez L, Ribera A, et al. Molecular characterization of the gene encoding a new AmpC β-lactamase in a clinical strain of Acinetobacter genomic species 3. Antimicrob Agents Chemother 2004; 48:1374-8.
11. Perilli M, Felici A, Oratore A, et al. Characterization of the chromosomal cephalosporinases produced by Acinetobacter Iwoffii and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 1996; 40:715-9.
12. Bou G, Martinez-Beltran J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000; 44:428-32.
13. Hujer KM, Hamza NS, Hujer AM, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005; 49:2941-8.
14. Segal H, Nelson EC, Elisha BG. Genetic environment and transcription of ampC in an Acinetobacter baumannii clinical isolate. Antimicrob Agents Chemother 2004; 48:612-4.
15. Segal H, Thomas R, Gay Elisha B. Characterization of class 1 integron resistance gene cassettes and the identification of a novel IS-like element in Acinetobacter baumannii. Plasmid 2003; 49:169-78.
16. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000; 38:3299-305.
17. Huang ZM, Mao PH, Chen Y, Wu L, Wu J. Study on the molecular epidemiology of SHV type β-lactamase-encoding genes of multipledrug-resistant Acinetobacter baumannii. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25:425-7.
18. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
19. Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 β-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol 2004; 42: 3978-84.
20. Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-9.
21. Yong D, Shin JH, Kim S, et al. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob Agents Chemother 2003; 47:1749-51.
22. Poirel L, Karim A, Mercat A, et al. Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother 1999; 43:157-8.
23. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003; 41: 3542-7.
24. Carbonne A, Naas T, Blanckaert K, et al. Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect 2005; 60:14-8.
25. Zarrilli R, Crispino M, Bagattini M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004; 42:946-53.
26. Brown S, Amyes SG. The sequences of seven class D β-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clin Microbiol Infect 2005; 11:326-9.
27. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18:306-13.
28. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonization and infection. Clin Microbiol Infect 2005; 11:540-6.
29. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000; 44:196-9.
30. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49:3198-202.
31. Navia MM, Ruiz J, Vila J. Characterization of an integron carrying a new class D β-lactamase (OXA-37) in Acinetobacter baumannii. Microb Drug Resist 2002; 8:261-5.
32. Vila J, Navia M, Ruiz J, Casals C. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 1997; 41:2757-9.
33. Poirel L, Gerome P, De Champs C, Stephanazzi J, Naas T, Nordmann P. Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:566-9.
34. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 2001; 45:447-53.
35. Yum JH, Yi K, Lee H, et al. Molecular characterization of metallo-β-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. J Antimicrob Chemother 2002; 49: 837-40.
36. Lee K, Ha GY, Shin BM, et al. Metallo-β-lactamase-producing gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMF-producing Acinetobacter spp. Diagn Microbiol Infect Dis 2004; 50:51-8.
37. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306-25.
38. Da Silva GJ, Correia M, Vital C, et al. Molecular characterization of bla(IMP-5), a new integron-borne metallo-β-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett 2002; 215:33-9.
39. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37:214-20.
40. Clark RB. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother 1996; 38:245-51.
41. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 2002; 40:4776-8.
42. Seward RJ, Lambert T, Towner KJ. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J Med Microbiol 1998; 47:455-62.
43. Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class I integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol 2004; 53:1233-40.
44. Vila J, Ruiz J, Goni P, Marcos A, Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995; 39:1201-3.
45. Vila J, Ruiz J, Goni P, Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997; 39:757-62.
46. Robicsek A, Sahm DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob Agents Chemother 2005; 49:3001-3.
47. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56: 463-9.
48. Magnet S, Courvalin P, Lambert T. Resistance-modulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45:3375-80.
49. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 2004; 48:3298-304.
50. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999; 43:882-9.
51. Tausk F, Stratton CW. Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1986; 30:584-9.
52. Livermore DM. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987; 6:439-45.
53. Boissinot M, Levesque RC. Nucleotide sequence of the PSE-4 carbenicillinase gene and correlations with the Staphylococcus aureus PC1 β-lactamase crystal structure. J Biol Chem 1990; 265:1225-30.
54. Huovinen P, Jacoby GA. Sequence of the PSE-1 β-lactamase gene. Antimicrob Agents Chemother 1991; 35:2428-30.
55. Lachapelle J, Dufresne J, Levesque RC. Characterization of the blaCARB-3 gene encoding the carbenicillinase-3 β-lactamase of Pseudomonas aeruginosa. Gene 1991; 102:7-12.
56. Sanschagrin F, Bejaoui N, Levesque RC. Structure of CARB-4 and AER-1 carbenicillin-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1998; 42:1966-72.
57. Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:1881-4.
58. Danel F, Hall LM, Gur D, Livermore DM. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997; 41:785-90.
59. Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:1362-6.
60. Thabaut A, Philippon A, Meyran M. β-lactamases of Pseudomonas aeruginosa and susceptibility against β-lactam antibiotics. Chemioterapia 1985; 4:36-42.
61. Philippon AM, Paul GC, Jacoby GA. New plasmid-mediated oxacillin-hydrolyzing β-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1986; 17:415-22.
62. Medeiros AA1 Cohenford M, Jacoby GA. Five novel plasmid-determined β-lactamases. Antimicrob Agents Chemother 1985; 27:715-9.
63. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-84.
64. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5:865-79.
65. Hall LM, Livermore DM, Gur D, Akova M, Akalin HE. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37:1637-44.
66. Danel F, Hall LM, Gur D, Livermore DM. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 1998; 42: 3117-22.
67. Mugnier P, Casin I, Bouthors AT, Collatz E. Novel OXA-10-derived extended-spectrum β-lactamases selected in vivo or in vitro. Antimicrob Agents Chemother 1998; 42:3113-6.
68. Mugnier P, Podglajen I, Goldstein FW, Collatz E. Carbapenems as inhibitors of OXA-13, a novel, integron-encoded β-lactamase in Pseudomonas aeruginosa. Microbiology 1998; 144:1021-31.
69. Philippon LN, Naas T, Bouthors AT, Barakett V, Nordmann P. OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41:2188-95.
70. Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM, Nordmann P. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45:1615-20.
71. Aubert D, Poirel L, Ali AB, Goldstein FW, Nordmann P. OXA-35 is an OXA-10-related β-lactamase from Pseudomonas aeruginosa. J Antimicrob Chemother 2001; 48:717-21.
72. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40:2488-93.
73. Poirel L, Ronco E, Naas T, Nordmann P. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5:651-2.
74. Dubois V, Arpin C, Noury P, Quentin C. Clinical strain of Pseudomonas aeruginosa carrying a blaTEM-21 gene located on a chromosomal interrupted TnA type transposon. Antimicrob Agents Chemother 2002; 46:3624-6.
75. Marchandin H, Jean-Pierre H, De Champs C, et al. Production of a TEM-24 plasmid-mediated extended-spectrum β-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:213-6.
76. Naas T, Philippon L, Poirel L, Ronco E, Nordmann P. An SHV-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:1281-4
77. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a, and VEB-1 extended-spectrum β-lactamases in gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 2001; 48:839-52.
78. Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47:3554-60.
79. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37:962-9.
80. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum β-lactamase from Pseudomonas aeruginosa and comparison with class A β-lactamases. Antimicrob Agents Chemother 1994; 38:104-14.
81. Claeys G, Verschraegen G, de Baere T, Vaneechoutte M. PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 2000; 45:924-5.
82. De Champs C, Poirel L, Bonnet R, et al. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46:3031-4.
83. Luzzaro F, Mantengoli E, Perilli M, et al. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 2001; 39:1865-70.
84. Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM. Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-β-lactamase and VIM-2 metallo-β-lactamase. Emerg Infect Dis 2001; 7:910-1.
85. Endimiani A, Luzzaro F, Pini B, Amicosante G, Rossolini GM, Toniolo AQ. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.
86. Naas T, Poirel L, Nordmann P. Molecular characterisation of In51, a class 1 integron containing a novel aminoglycoside adenylyltransferase gene cassette, aadA6, in Pseudomonas aeruginosa. Biochim Biophys Acta 1999; 1489:445-51.
87. Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial spread of the integron-located VEB-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis 2002; 34:603-11.
88. Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P. VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 2001; 7:468-70.
89. GES-1 and a fused product of aac3-Ib/aac6′-Ib′ gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:638-45.
90. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45:2598-603.
91. Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002; 49:561-5.
92. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS. An integron-assodated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1. J Antimicrob Chemother 2001; 48:627-30.
93. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002; 8:321-31.
94. Toleman MA, Simm AM, Murphy TA, et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002; 50:673-9.
95. Murphy TA, Simm AM, Toleman MA, Jones RN, Walsh TR. Biochemical characterization of the acquired metallo-β-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2003; 47:582-7.
96. Osano E, Arakawa Y, Wacharotayankun R, et al. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 1994; 38:71-8.
97. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:349-53.
98. Hirakata Y, Yamaguchi T, Nakano M, et al. Clinical and bacteriological characteristics of IMF-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:26-32.
99. IMP-7. Antimicrob Agents Chemother 2002; 46:255-8.
100. Ho SE, Subramaniam G, Palasubramaniam S, Navaratnam P. Carbapenem-resistant Pseudomonas aeruginosa in Malaysia producing IMP-7 β-lactamase. Antimicrob Agents Chemother 2002; 46:3286-7.
101. IMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J Antimicrob Chemother 2003; 52:583-90.
102. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin Infect Dis 2000; 31:1119-25.
103. Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38:1290-2.
104. Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44:891-7.
105. VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 2001; 45:546-52.
106. Cardoso O, Leitao R, Figueiredo A, Sousa JC, Duarte A, Peixe LV. Metallo-β-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb Drug Resist 2002; 8:93-7.
107. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC. Spread of integron-associated VIM-type metallo-β-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 2003; 41:822-5.
108. Mavroidi A, Tsakris A, Tzelepi E, Pournaras S, Loukova V, Tzouvelekis LS. Carbapenem-hydrolysing VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa from Greece. J Antimicrob Chemother 2000; 46: 1041-2.
109. Sardelic S, Pallecchi L, Punda-Polic V, Rossolini GM. Carbapenem-resistant Pseudomonas aeruginosa carrying VIM-2 metallo-β- lactamase determinants, Croatia. Emerg Infect Dis 2003; 9:1022-3.
110. Oh EJ, Lee S, Park YJ, et al. Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean university hospital and comparison of screening methods for detecting metallo-β- lactamase. J Microbiol Methods 2003; 54:411-8.
111. VIM-2 cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002; 46:1053-8.
112. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMF-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9:868-71.
113. Yan JJ, Hsueh PR, Ko WC, et al. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45:2224-8.
114. Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41:5407-13.
115. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005; 49:3538-40.
116. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36:2046-8.
117. Horii T, Muramatsu H, Morita M, Maekawa M. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy. Microb Drug Resist 2003; 9:223-9.
118. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
119. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-82.
120. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized com-parison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
121. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309-13.
122. Miller GH, Sabatelli FJ, Hare RS, et al. The most frequent amino-glycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997; 24(Suppl 1):S46-62.
123. Pitt TL, Livermore DM, Miller G, Vatopoulos A, Legakis NJ. Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. J Antimicrob Chemother 1990; 26:319-28.
124. Vanhoof R, Godard C, Nulens E, et al. Serotypes and extended spectrum β-lactam resistance in aminoglycoside resistant Pseudomonas aeruginosa isolates from two Belgian general hospitals: a seven year study. J Hosp Infect 1993; 24:129-38.
125. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR, and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21:409-13.
126. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-40.
127. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999; 43:1085-90.
128. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34:257-61.
129. Deplano A, Denis O, Poirel L, et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J Clin Microbiol 2005; 43:1198-204.
130. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 2006; 311:374-7.
131. Obara M, Nakae T. Mechanisms of resistance to β-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother 1991; 28: 791-800.